TORNTPHARM.NS Profit & Loss
Torrent Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 00:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹96.20 Bn | ₹107.28 Bn | ₹115.16 Bn | ₹139.80 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹0.45 Bn | ₹0.58 Bn | ₹0.23 Bn | ₹-0.94 Bn | OtherIncome |
| Total Income | ₹96.65 Bn | ₹107.86 Bn | ₹115.39 Bn | ₹138.86 Bn | Income |
| Cost of Materials Consumed | ₹14.80 Bn | ₹16.57 Bn | ₹15.20 Bn | ₹17.58 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹10.89 Bn | ₹11.84 Bn | ₹15.31 Bn | ₹16.19 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹1.66 Bn | ₹-1.55 Bn | ₹-2.75 Bn | ₹0.11 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹16.78 Bn | ₹19.84 Bn | ₹22.03 Bn | ₹26.71 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹3.33 Bn | ₹3.54 Bn | ₹2.52 Bn | ₹3.85 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹7.07 Bn | ₹8.08 Bn | ₹7.95 Bn | ₹11.19 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹23.65 Bn | ₹26.90 Bn | ₹28.16 Bn | ₹33.62 Bn | OtherExpenses |
| Total Expenses | ₹78.18 Bn | ₹85.22 Bn | ₹88.42 Bn | ₹109.25 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹18.47 Bn | ₹22.64 Bn | ₹26.97 Bn | ₹29.61 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Bn | ₹0.88 Bn | ₹-0.24 Bn | ₹-0.89 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹18.47 Bn | ₹23.52 Bn | ₹26.73 Bn | ₹28.72 Bn | ProfitBeforeTax |
| Tax Expense | ₹6.02 Bn | ₹6.96 Bn | ₹7.62 Bn | ₹7.34 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹12.45 Bn | ₹16.56 Bn | ₹19.11 Bn | ₹21.38 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹12.45 Bn | ₹16.56 Bn | ₹19.11 Bn | ₹21.63 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹36.79 | ₹48.94 | ₹56.47 | ₹63.92 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹36.79 | ₹48.94 | ₹56.47 | ₹63.92 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from TORNTPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).